Well, one IPO we were eagerly awaiting is no longer on this year’s docket with Tekmira’s (NASDAQ:TKMR) merger agreement with Oncore announced tonight …
Entry: $9.86 10/2/14 Take Profits: $14.
In a research report issued today, Alpha BioPharma’s Paul Nunzio DeSantis initiated coverage on shares of GlobeImmune (NASDAQ:GBIM) with a Buy rating and $17 price target, which represents …
Big Picture Thesis: Since Afrezza’s approval MannKind’s (NASDAQ:MNKD) shares have declined more than 50% as enthusiasm for their partnership with Sanofi-Aventis (NYSE:SNY) has …
In a research report released today, Alpha BioPharma’s Paul Nunzio DeSantis initiated coverage on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) with a Buy rating and $16 price …
Investment Thesis We expect volatility in the share prices of HCV focused companies leading into this year’s AASLD meeting from November 7th to …
